| Literature DB >> 25248727 |
Tamam El-Elimat1, Huzefa A Raja1, Mario Figueroa1, Steven M Swanson2, Joseph O Falkinham3, David M Lucas4, Michael R Grever5, Mansukh C Wani6, Cedric J Pearce7, Nicholas H Oberlies1.
Abstract
As part of an ongoing project to explore filamentous fungi for anticancer and antibiotic leads, 11 compounds were isolated and identified from an organic extract of the fungus Scytalidium album (MSX51631) using bioactivity-directed fractionation against human cancer cell lines. Of these, eight compounds were a series of sorbicillinoid analogs (1-8), of which four were new (scalbucillin A (2), scalbucillin B (3), scalbucillin C (6) and scalbucillin D (8)), two were phthalides (9-10) and one was naphthalenone (11). Compounds (1-11) were tested in the MDA-MB-435 (melanoma) and SW-620 (colon) cancer cell lines. Compound 1 was the most potent with IC50 values of 1.5 and 0.5 μM, followed by compound 5 with IC50 values of 2.3 and 2.5 μM at 72 h. Compound 1 showed a 48-h IC50 value of 3.1 μM when tested against the lymphocytic leukemia cell line OSU-CLL, while the nearly identical compound 5 had almost no activity in this assay. Compounds 1 and 5 showed selective and equipotent activity against Aspergillus niger with minimum IC values of 0.05 and 0.04 μg ml(-1) (0.20 and 0.16 μM), respectively. The in vitro hemolytic activity against sheep erythrocytes of compounds 1 and 5 was investigated and were found to provoke 10% hemolysis at 52.5 and 45.0 μg ml(-1), respectively, indicative of a promising safety factor.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25248727 PMCID: PMC4372511 DOI: 10.1038/ja.2014.125
Source DB: PubMed Journal: J Antibiot (Tokyo) ISSN: 0021-8820 Impact factor: 2.649
Figure 1Structure of compounds (1 – 11) isolated from S. album.
1H NMR data for compounds 2, 3, 6 and 8 (in CDC13, 700 MHz for 2 and 3 and 500 MHz for 6 and 8, chemical shifts in ppm, coupling constants in Hz)
|
| 2 | 3 | 6 | 8 |
|---|---|---|---|---|
|
| ||||
| δ | δ | δ | δ | |
| 1 | — | — | — | — |
| 2 | 7.05, d (14.6) | 6.95, d (15.0) | 3.02, dd (7.5, 6.9) | 2.95, dd (8.0, 7.5) |
| 3 | 7.54, dd (14.6, 9.9) | 7.49, dd (15.0, 10.6) | 2.41, ddd (7.5, 6.9, 6.3) | 2.40, ddd (8.0, 7.5, 5.2) |
| 4 | 6.39, m | 6.34, m | 5.49, dtq (15.5, 6.3, 1.2) | 5.49, dtq (15.5, 5.2, 0.6) |
| 5 | 6.38, dq (14.6, 5.1) | 6.31, dq (15.0, 6.4) | 5.50, dq (15.5, 6.3) | 5.50, dq (15.5, 5.2) |
| 6 | 1.94, d (5.1) | 1.92, dd (6.4, 0.6) | 1.65, dd (6.3, 1.2) | 1.65, dd (5.2, 0.6) |
| 1' | — | — | — | — |
| 2' | — | — | — | — |
| 3' | 6.58, s | 6.46, s | 6.47, s | 6.37, s |
| 4' | — | — | — | — |
| 5' | — | — | — | — |
| 6' | 8.74, s | 7.71, s | 8.37, s | 7.44, s |
| 7' | — | 4.64, d (6.1) | — | — |
| 8' | 4.12, s | 3.90, s | 3.88, s | 3.84, s |
| 9' | — | — | 3.93, s | — |
| 2'-OH | 13.87, s | 13.58, s | 13.05, s | 12.79, s |
| 7'-OH | 10.05, bs | 2.02, t (6.1) | — | — |
Abbreviations: Mult., multiplicity.
13C NMR data for compounds 2, 3, 6 and 8 (in CDC13, 175 MHz for 2 and 3, and 125 MHz for 6 and 8, chemical shifts in ppm)
|
| 2 | 3 | 6 | 8 |
|---|---|---|---|---|
|
| ||||
|
δ
|
δ
|
δ
|
δ
| |
| 1 | 192.8 | 192.4 | 204.7 | 204.2 |
| 2 | 120.6 | 121.4 | 38.0 | 38.0 |
| 3 | 146.9 | 145.1 | 27.2 | 27.5 |
| 4 | 130.4 | 130.4 | 129.2 | 129.6 |
| 5 | 143.5 | 141.8 | 126.6 | 126.2 |
| 6 | 19.1 | 19.0 | 18.0 | 18.0 |
| 1′ | 115.1 | 113.3 | 112.9 | 112.7 |
| 2′ | 169.6 | 166.5 | 167.9 | 164.0 |
| 3′ | 100.5 | 99.7 | 100.5 | 99.0 |
| 4′ | 163.1 | 163.8 | 165.5 | 164.3 |
| 5′ | 109.2 | 120.7 | 111.6 | 118.1 |
| 6′ | 137.2 | 129.9 | 135.9 | 131.1 |
| 7′ | 164.3 | 61.2 | 165.4 | 15.8 |
| 8′ | 57.2 | 55.8 | 52.2 | 55.8 |
| 9' | — | — | 56.5 | — |
Figure 2Key HMBC and COSY correlations of compounds 2, 3, 6, and 8.
Activity of compounds 1–11 against two human tumor cell lines
| IC50 values in μM[ | ||
|---|---|---|
| Compound[ | MDA-MB-435[ | SW-620[ |
|
| 1.5 | 0.5 |
|
| 67.9 | 16.0 |
|
| 65.2 | 15.1 |
|
| 2.3 | 2.5 |
Compounds 2 and 6–11 were inactive.
IC50 values were determined as the concentration required to inhibit growth to 50% of control with a 72 h incubation.
Positive control was vinblastine tested at concentration of 1 nM in MDA-MB-435 cells and 10 nM in SW620 cells, which had 48% and 30% viable cells, respectively.
Antifungal and hemolytic activity of compounds 1, 3, and 5
| Minimal inhibitory concentration (μg/ml) | 10% Hemolysis (μg/ml)[ | Safety factor[ | |||
|---|---|---|---|---|---|
| Compound | C. albicans | C. neoformans | A. niger | ||
|
| >53 | >53 | 0.05 | 52.5 | 1050 |
|
| >38 | >38 | 0.60 | 37.5 | 62.5 |
|
| >45 | >45 | 0.04 | 45.0 | 1125 |
| Amphotericin B[ | 16 | 8 | 31 | 62.5 | 2.0 |
| Triton X-100[ | NT | NT | NT | 0.40 | NA |
Hemolytic activity is the concentration required to provoke 10% hemolysis
Safety factor was calculated as the concentration inducing 10% hemolysis over MIC against A niger.
Positive controls.
Abbreviations: NT. not tested. NA. not available.